Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer
Effect of human leukocyte antigen class I expression of tumor cells on outcome of intravesical instillation of bacillus Calmette-Guerin immunotherapy for bladder cancer
复制标题
DOI：
10.1158/1078-0432.ccr-06-0595
复制
发表时间：
2006-08-01
影响因子：
11.5
通讯作者：
Tsukamoto, Taiji
中科院分区：
文献类型：
--
作者：
Kitamura, Hiroshi;Torigoe, Toshihiko;Tsukamoto, Taiji
目的：各种免疫系统在卡介苗膀胱灌注治疗膀胱癌的临床疗效中起着重要作用。然而，人类白细胞抗原（HLA）I类分子的肿瘤细胞和各种免疫系统细胞浸润到/周围的肿瘤尚未进行评估，虽然许多预后因素，包括临床，病理和分子，已被调查。本研究的目的是确定免疫预后因素的BCG免疫治疗膀胱cancer.Experimental设计：免疫组化染色HLA I类，CD 4，CD 8，CD 20，CD 68，TIA-1，S-100，和FOXP 3进行了标本从30例接受BCG免疫治疗，从他们的治疗前和治疗后标本。我们对影响无复发生存率的因素进行了单变量和多变量分析。阳性，弱阳性，和阴性组的细胞浸润到/周围的肿瘤进行了比较，使用Kaplan-Meier法和log-rank test.Results：HLA I类是一个显着的预后因素，无论是在单变量和多变量分析的无复发survival。HLA I类抗原阳性和阴性患者的5年无复发生存率分别为55.7%和19.1%（P = 0.019）。BCG治疗后CD 8、CD 20、CD 68阳性细胞浸润与治疗效果显著相关。结论：肿瘤细胞HLA I类分子的表达与BCG免疫治疗膀胱癌的疗效密切相关。提示CTL可能是该疗法的主要效应细胞之一。
Purpose: Various immune systems play important roles in the clinical efficacy of intravesical Bacillus Calmette-Guerin (BCG) instillation for bladder cancer. However, human leukocyte antigen (HLA) class I molecules on tumor cells and various immune system cells infiltrating to/around the tumor have not been evaluated, although many prognostic factors, including clinical, pathologic, and molecular ones, have been investigated. The aim of this study was to determine immunologic prognostic factors of BCG immunotherapy for bladder cancer.Experimental Design: Immunohistochemical staining for HLA class I, CD4, CD8, CD20, CD68, TIA-1, S-100, and FOXP3 was carried out on specimens from 30 patients who underwent BCG immunotherapy from whom both pretreatment and posttreatment specimens were obtained. We did univariate and multivariate analyses of factors affecting recurrence-free survival. The positive, weakly positive, and negative groups of cells that infiltrated to/around the tumor were compared with recurrence-free survival using the Kaplan-Meier method and log-rank test.Results: HLA class I was a significant prognostic factor both in univariate and multivariate analyses. The 5-year recurrence-free survivals of the patients with HLA class I - positive tumors and those with HLA class I - negative tumors were 55.7% and 19.1%, respectively (P = 0.019). There was a significant association between infiltration of CD8, CD20, and CD68-positive cells after BCG therapy and therapeutic effects.Conclusions: Our data show that expression of HLA class I molecules on tumor cells contributes significantly to the therapeutic effect of BCG immunotherapy for bladder cancer. It is suggested that CTLs may be one of main effectors in this therapy.